Furthermore, loss-of-function (LOF) mutations in Axin1 have been identified in approximately 3–16% of HCC patients, whereas Axin2 mutations are present in approximately 3% of HCC patients (40–43). This evidence concerns the gene AXIN1 and hepatocellular carcinoma.